Form 4: Kineta Chief Scientific Officer Disposes of Shares and Options Following TuHURA Merger

Kineta, Inc.'s Chief Scientific Officer, Thierry Guillaudeux, has reported the disposition of all his common stock and stock options in Kineta following the company's merger with TuHURA Biosciences, Inc.

Summary

• Thierry Guillaudeux, Chief Scientific Officer of Kineta, Inc., reported the disposition of his beneficial ownership in Kineta, Inc. common stock and derivative securities.
• The disposition occurred on June 30, 2025, pursuant to the Agreement and Plan of Merger dated December 11, 2024, and amended May 5, 2025, between TuHURA Biosciences, Inc. and Kineta, Inc.
• Under the merger agreement, each outstanding share of Kineta common stock was cancelled and converted into the right to receive 0.185298 shares of TuHURA Common Stock.
• Kineta common stock holders are also entitled to a pro rata portion of 1,129,884 shares of TuHURA Common Stock to be issued six months following the closing of the mergers, subject to adjustment for losses.
• Additionally, Kineta common stock holders have the right to a pro rata share of cash consideration from disposed legacy Kineta assets.
• All options to purchase Kineta Common Stock with an exercise price greater than $0.64 were cancelled and extinguished for no consideration at the effective time of the First Merger.
• Mr. Guillaudeux disposed of 217,333 shares of Kineta Common Stock.
• He also disposed of stock options to buy a total of 146,890 shares of Kineta Common Stock, with exercise prices ranging from $3.28 to $29.06.
• Following these transactions, Mr. Guillaudeux beneficially owns 0 shares of Kineta Common Stock and 0 derivative securities.

Sentiment

Score: 5

Explanation: The document is a factual report of a required insider transaction following a merger. While the cancellation of certain options for no consideration is a negative for the reporting person, the merger itself is a strategic corporate event, and the Form 4 primarily serves as a disclosure of the resulting change in beneficial ownership, making the overall sentiment neutral from a broader market perspective.

Positives

• The merger with TuHURA Biosciences, Inc. allows Kineta shareholders to receive equity in the combined entity, potentially offering continued participation in future growth.
• The merger provides for additional consideration to Kineta shareholders, including a pro rata portion of 1,129,884 shares of TuHURA Common Stock and cash from disposed legacy assets.

Negatives

• Stock options with an exercise price greater than $0.64 were cancelled for no consideration, resulting in a loss of potential value for the reporting person and other option holders.

Risks

• The issuance of 1,129,884 shares of TuHURA Common Stock six months post-merger is subject to adjustment for losses incurred or accrued during that six-month period, which could reduce the final number of shares received.

Future Outlook

Kineta shareholders are expected to receive additional TuHURA Common Stock approximately six months following the closing of the mergers, subject to potential adjustments based on losses incurred during that period. They are also entitled to a pro rata share of cash from disposed legacy Kineta assets.

Industry Context

This filing reflects a common strategic move in the biotechnology and pharmaceutical sectors, where smaller companies like Kineta merge with or are acquired by larger entities like TuHURA Biosciences to consolidate assets, intellectual property, and market position, often aiming for greater operational efficiency or expanded pipelines.

Stakeholder Impact

• Kineta shareholders: Their shares were converted into TuHURA Common Stock, and they are entitled to additional future share and cash consideration.
• Kineta option holders (including the reporting person): Options with an exercise price above $0.64 were cancelled for no consideration, resulting in a loss of potential value.

Next Steps

• Issuance of a pro rata portion of 1,129,884 shares of TuHURA Common Stock to former Kineta shareholders approximately six months following the closing of the mergers.
• Distribution of pro rata cash consideration to former Kineta shareholders from disposed legacy Kineta assets.

Key Dates

Keywords

Merger, SEC Form 4, Beneficial Ownership, Stock Options, Common Stock, Insider Transaction, Kineta Inc., TuHURA Biosciences Inc., KANT, Disposition of Securities, Corporate Action